This study examined treatment-free survival (TFS) outcomes in non-small cell lung cancer (NSCLC) patients who completed a two-year course of immune checkpoint inhibitor (ICI) therapy, using the Korean Health Insurance Review and Assessment Service (HIRA) database.
The study characterized TFS rates and clinical outcomes following completion of the standard two-year ICI treatment limit in NSCLC patients in a real-world Korean population, though specific numerical results were not available in the provided source text.
The study relies on administrative claims data (HIRA), which may lack granular clinical detail such as performance status, tumor histology subtype, or biomarker data; findings reflect a single-country healthcare system and may not generalize globally.
Clinicians managing NSCLC patients who complete two years of ICI therapy should monitor for sustained treatment-free remission, as real-world data from large national databases can help guide expectations for durability of response after stopping ICIs.
Explore related topics
